Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-guided Adjuvant Chemotherapy in Urothelial Carcinoma
NCT06257017Phase 2Completed
- Sponsor
- Yungjin Pharmaceutical
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, Cisplatin micelle injection (HA132) in urothelial carcinoma (UC), sponsored by Yungjin Pharmaceutical. Started Feb 2024; status: completed.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06257017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06257017.